Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study.

Abstract:

INTRODUCTION:Primary breast cancer involving four or more axillary lymph nodes carries a poor prognosis. We hypothesized that use of an immunohistochemical biomarker scoring system could allow for identification of variable risk subgroups. METHODS:Patients with four or more positive axillary nodes were identified from a clinically annotated tissue microarray of formalin-fixed paraffin-embedded primary breast cancers and randomized into a 'test set' and a 'validation set'. A prospectively defined prognostic scoring model was developed in the test set and was further assessed in the validation set combining expression for eight biomarkers by immunohistochemistry, including estrogen receptor, human epidermal growth factor receptors 1 and 2, carbonic anhydrase IX, cytokeratin 5/6, progesterone receptor, p53 and Ki-67. Survival outcomes were analyzed by the Kaplan-Meier method, log rank tests and Cox proportional-hazards models. RESULTS:A total of 313 eligible patients were identified in the test set for whom 10-year relapse-free survival was 38.3% (SEM 2.9%), with complete immunohistochemical data available for 227. Tumor size, percentage of positive axillary nodes and expression status for the progesterone receptor, Ki-67 and carbonic anhydrase IX demonstrated independent prognostic significance with respect to relapse-free survival. Our combined biomarker scoring system defined three subgroups in the test set with mean 10-year relapse-free survivals of 75.4% (SEM 7.0%), 35.3% (SEM 4.1%) and 19.3% (SEM 7.0%). In the validation set, differences in relapse-free survival for these subgroups remained statistically significant but less marked. CONCLUSION:Biomarkers assessed here carry independent prognostic value for breast cancer with four or more positive axillary nodes and identified clinically relevant prognostic subgroups. This approach requires refinement and validation of methodology.

journal_name

Breast Cancer Res

authors

Crabb SJ,Bajdik CD,Leung S,Speers CH,Kennecke H,Huntsman DG,Gelmon KA

doi

10.1186/bcr1847

subject

Has Abstract

pub_date

2008-01-01 00:00:00

pages

R6

issue

1

eissn

1465-5411

issn

1465-542X

pii

bcr1847

journal_volume

10

pub_type

杂志文章,随机对照试验
  • Prognostic stromal gene signatures in breast cancer.

    abstract:INTRODUCTION:Global gene expression analysis of tumor samples has been a valuable tool to subgroup tumors and has the potential to be of prognostic and predictive value. However, tumors are heterogeneous, and homogenates will consist of several different cell types. This study was designed to obtain more refined expres...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0530-2

    authors: Winslow S,Leandersson K,Edsjö A,Larsson C

    更新日期:2015-02-21 00:00:00

  • Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

    abstract:BACKGROUND:Several anthropometric measures have been found to be associated with the risk of breast cancer. Current weight, body mass index, and adult weight gain appear to be predictors of postmenopausal breast cancer. These factors have been associated with a reduced risk of premenopausal breast cancer. We asked whet...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1293

    authors: Kotsopoulos J,Olopado OI,Ghadirian P,Lubinski J,Lynch HT,Isaacs C,Weber B,Kim-Sing C,Ainsworth P,Foulkes WD,Eisen A,Sun P,Narod SA

    更新日期:2005-01-01 00:00:00

  • The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy.

    abstract::Despite the progress achieved in breast cancer screening and therapeutic innovations, the basal-like subtype of breast cancer (BLBC) still represents a particular clinical challenge. In order to make an impact on survival in this type of aggressive breast cancer, new targeted therapeutic agents are urgently needed. Ab...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr3401

    authors: Hui M,Cazet A,Nair R,Watkins DN,O'Toole SA,Swarbrick A

    更新日期:2013-03-28 00:00:00

  • Nighttime eating and breast cancer among Chinese women in Hong Kong.

    abstract:BACKGROUND:A novel line of research suggests that eating at nighttime may have several metabolic consequences that are highly relevant to breast cancer. We investigated the association between nighttime eating habits after 10 p.m. and breast cancer in Hong Kong women. METHODS:A hospital-based case-control study was co...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-017-0821-x

    authors: Li M,Tse LA,Chan WC,Kwok CH,Leung SL,Wu C,Yu WC,Lee PM,Tsang KH,Law SH,Vermeulen R,Gu F,Caporaso NE,Yu IT,Wang F,Yang XR

    更新日期:2017-03-17 00:00:00

  • Whither high-dose chemotherapy in breast cancer?

    abstract::Four trials of high-dose chemotherapy with stem cell support in breast cancer in the adjuvant and metastatic settings have shown no long-term disease-free or overall survival gain. This relative failure of a single high-dose therapy we believe opens up the development of a dose-dense approach with block scheduling as ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr262

    authors: Mayer A,Earl H

    更新日期:2001-01-01 00:00:00

  • Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways.

    abstract:INTRODUCTION:Although aberrant tyrosine kinase signalling characterises particular breast cancer subtypes, a global analysis of tyrosine phosphorylation in mouse models of breast cancer has not been undertaken to date. This may identify conserved oncogenic pathways and potential therapeutic targets. METHODS:We applied...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-014-0437-3

    authors: Ali NA,Wu J,Hochgräfe F,Chan H,Nair R,Ye S,Zhang L,Lyons RJ,Pinese M,Lee HC,Armstrong N,Ormandy CJ,Clark SJ,Swarbrick A,Daly RJ

    更新日期:2014-09-09 00:00:00

  • From Bittner to Barr: a viral, diet and hormone breast cancer aetiology hypothesis.

    abstract::It is hypothesized that the human homologue of the mouse mammary tumour virus (HHMMTV) and other viruses, such as human papillomavirus (HPV) and Epstein-Barr virus (EBV), act as cofactors with diet, oestrogens and other hormones in the initiation and promotion of some types of breast cancer in genetically susceptible ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr275

    authors: Lawson JS,Tran D,Rawlinson WD

    更新日期:2001-01-01 00:00:00

  • Gene expression in murine mammary epithelial stem cell-like cells shows similarities to human breast cancer gene expression.

    abstract:INTRODUCTION:Mammary stem cells are bipotential and suggested to be the origin of breast cancer development, but are elusive and vaguely characterized. Breast tumors can be divided into subgroups, each one requiring specific treatment. To determine a possible association between mammary stem cells and breast cancer, a ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2256

    authors: Williams C,Helguero L,Edvardsson K,Haldosén LA,Gustafsson JA

    更新日期:2009-01-01 00:00:00

  • Can the breast screening appointment be used to provide risk assessment and prevention advice?

    abstract::Breast cancer risk is continuing to increase across all societies with rates in countries with traditionally lower risks catching up with the higher rates in the Western world. Although cure rates from breast cancer have continued to improve such that absolute numbers of breast cancer deaths have dropped in many count...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0595-y

    authors: Evans DG,Howell A

    更新日期:2015-07-09 00:00:00

  • PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer.

    abstract:INTRODUCTION:The aim of this study was to develop and validate a prognostication model to predict overall and breast cancer specific survival for women treated for early breast cancer in the UK. METHODS:Using the Eastern Cancer Registration and Information Centre (ECRIC) dataset, information was collated for 5,694 wom...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2464

    authors: Wishart GC,Azzato EM,Greenberg DC,Rashbass J,Kearins O,Lawrence G,Caldas C,Pharoah PD

    更新日期:2010-01-01 00:00:00

  • Circulating DNA as biomarker in breast cancer.

    abstract::As the release of tumor-associated DNA into blood circulation is a common event in patients with cancer, screening of plasma or serum DNA may provide information on genetic and epigenetic profiles associated with breast cancer development, progression, and response to therapy. Quantitative testing of circulating DNA c...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/s13058-015-0645-5

    authors: Schwarzenbach H,Pantel K

    更新日期:2015-10-09 00:00:00

  • Frequency of breast cancer subtypes among African American women in the AMBER consortium.

    abstract:BACKGROUND:Breast cancer subtype can be classified using standard clinical markers (estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)), supplemented with additional markers. However, automated biomarker scoring and classification schemes have not been standardized. T...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-018-0939-5

    authors: Allott EH,Geradts J,Cohen SM,Khoury T,Zirpoli GR,Bshara W,Davis W,Omilian A,Nair P,Ondracek RP,Cheng TD,Miller CR,Hwang H,Thorne LB,O'Connor S,Bethea TN,Bell ME,Hu Z,Li Y,Kirk EL,Sun X,Ruiz-Narvaez EA,Perou CM

    更新日期:2018-02-06 00:00:00

  • Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer.

    abstract::Transforming growth factor-beta (TGF-beta) is a tumor suppressor, the function of which is compromised in many types of human cancer, including breast cancer. The tumor suppressive effects of TGF-beta are caused by potent inhibition of cell proliferation due to cell cycle arrest in the G1 phase. Such antiproliferative...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr42

    authors: Kretzschmar M

    更新日期:2000-01-01 00:00:00

  • Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy: an inflammatory situation.

    abstract::Targeting the function of epidermal growth factor receptor (EGFR) has failed as an effective clinical option for breast cancer. Understanding the drivers of inherent resistance has been a challenge. One possible mechanism is the acquisition of stem-like properties through the process of epithelial-mesenchymal transiti...

    journal_title:Breast cancer research : BCR

    pub_type: 评论,杂志文章

    doi:10.1186/s13058-014-0448-0

    authors: Brown WS,Wendt MK

    更新日期:2014-09-23 00:00:00

  • Genotypes and haplotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent upon menopausal status.

    abstract:INTRODUCTION:MBD2, the gene encoding methyl-CpG-binding domain (MBD)2, is a major methylation related gene and functions as a transcriptional repressor that can specifically bind to the methylated regions of other genes. MBD2 may also mediate gene activation because of its potential DNA demethylase activity. The presen...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1283

    authors: Zhu Y,Brown HN,Zhang Y,Holford TR,Zheng T

    更新日期:2005-01-01 00:00:00

  • Prenylation inhibitors stimulate both estrogen receptor alpha transcriptional activity through AF-1 and AF-2 and estrogen receptor beta transcriptional activity.

    abstract:INTRODUCTION:We showed in a previous study that prenylated proteins play a role in estradiol stimulation of proliferation. However, these proteins antagonize the ability of estrogen receptor (ER) alpha to stimulate estrogen response element (ERE)-dependent transcriptional activity, potentially through the formation of ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr956

    authors: Cestac P,Sarrabayrouse G,Médale-Giamarchi C,Rochaix P,Balaguer P,Favre G,Faye JC,Doisneau-Sixou S

    更新日期:2005-01-01 00:00:00

  • A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival.

    abstract:BACKGROUND:Breast cancer intrinsic molecular subtype (IMS) as classified by the expression-based PAM50 assay is considered a strong prognostic feature, even when controlled for by standard clinicopathological features such as age, grade, and nodal status, yet the molecular testing required to elucidate these subtypes i...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-1248-3

    authors: Jaber MI,Song B,Taylor C,Vaske CJ,Benz SC,Rabizadeh S,Soon-Shiong P,Szeto CW

    更新日期:2020-01-28 00:00:00

  • An investigation of soy intake and mammographic characteristics in Hawaii.

    abstract::This cross-sectional investigation in Hawaii explored the relation between soy foods and mammographic characteristics using two food frequency questionnaires and a computer-assisted density assessment method. Japanese and Chinese women reported significantly greater soy food intake than Caucasian women. Whereas soy in...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr285

    authors: Maskarinec G,Meng L

    更新日期:2001-01-01 00:00:00

  • Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

    abstract:INTRODUCTION:Gene expression analysis is used to subtype breast cancers such that the most aggressive tumors are identified, but translating this into clinical practice can be cumbersome. Our goal is to develop a universal biomarker that distinguishes patients at high risk across all breast cancer subtypes. We previous...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2156

    authors: Habibi G,Leung S,Law JH,Gelmon K,Masoudi H,Turbin D,Pollak M,Nielsen TO,Huntsman D,Dunn SE

    更新日期:2008-01-01 00:00:00

  • A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.

    abstract:INTRODUCTION:Estrogen receptor-alpha (ER-alpha) and progesterone receptor (PgR) are consolidated predictors of response to hormonal therapy (HT). In contrast, little information regarding the role of estrogen receptor-beta (ER-beta) in various breast cancer risk groups treated with different therapeutic regimens is ava...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2139

    authors: Novelli F,Milella M,Melucci E,Di Benedetto A,Sperduti I,Perrone-Donnorso R,Perracchio L,Venturo I,Nisticò C,Fabi A,Buglioni S,Natali PG,Mottolese M

    更新日期:2008-01-01 00:00:00

  • Progestin effects on cell proliferation pathways in the postmenopausal mammary gland.

    abstract:INTRODUCTION:Menopausal hormone therapies vary widely in their effects on breast cancer risk, and the mechanisms underlying these differences are unclear. The primary goals of this study were to characterize the mammary gland transcriptional profile of estrogen + progestin therapy in comparison with estrogen-alone or t...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3456

    authors: Wood CE,Branstetter D,Jacob AP,Cline JM,Register TC,Rohrbach K,Huang LY,Borgerink H,Dougall WC

    更新日期:2013-01-01 00:00:00

  • Clinical trial update: National Cancer Institute of Canada.

    abstract::The Breast Cancer Site Group (BCSG) of the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) has conducted a wide variety of clinical trials focussing on large phase III trials of adjuvant chemotherapy, adjuvant hormonal therapy, and optimal delivery of adjuvant radiation therapy. The Group has al...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr979

    authors: Pritchard K,Whelan T

    更新日期:2005-01-01 00:00:00

  • The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer.

    abstract::Testosterone binds to the androgen receptor in target tissue to mediate its effects. Variations in testosterone levels and androgen receptor activity may play a role in the etiology of breast cancer. Here, we review the epidemiologic evidence linking endogenous testosterone to breast cancer risk. Paradoxically, result...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr593

    authors: Lillie EO,Bernstein L,Ursin G

    更新日期:2003-01-01 00:00:00

  • The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis.

    abstract:INTRODUCTION:Matrix metalloproteinase (MMP)-2 is very active at degrading extracellular matrix. It is under the influence of an activator, membrane type 1 MMP (MMP-14), and the tissue inhibitor of metalloproteases (TIMP)-2. We hypothesized that the individual expression of these three markers or their balance may help ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1503

    authors: Têtu B,Brisson J,Wang CS,Lapointe H,Beaudry G,Blanchette C,Trudel D

    更新日期:2006-01-01 00:00:00

  • Biology of breast cancer in young women.

    abstract::Breast cancer arising at a young age is relatively uncommon, particularly in the developed world. Several studies have demonstrated that younger patients often experience a more aggressive disease course and have poorer outcome compared to older women. Expression of key biomarkers, including endocrine receptors, HER2 ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/s13058-014-0427-5

    authors: Azim HA Jr,Partridge AH

    更新日期:2014-08-27 00:00:00

  • Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers.

    abstract:INTRODUCTION:BRCA1 and BRCA2 mutation carriers are at increased risk for developing both breast and ovarian cancer. It has been suggested that carriers of BRCA1/2 mutations may also be at increased risk of having recurrent (three or more) miscarriages. Several reproductive factors have been shown to influence the risk ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究

    doi:10.1186/bcr1387

    authors: Friedman E,Kotsopoulos J,Lubinski J,Lynch HT,Ghadirian P,Neuhausen SL,Isaacs C,Weber B,Foulkes WD,Moller P,Rosen B,Kim-Sing C,Gershoni-Baruch R,Ainsworth P,Daly M,Tung N,Eisen A,Olopade OI,Karlan B,Saal HM,Garber

    更新日期:2006-01-01 00:00:00

  • Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.

    abstract:INTRODUCTION:Human epidermal growth factor receptor HER3 has been implicated in promoting the aggressiveness and metastatic potential of breast cancer. Upregulation of HER3 has been found to be a major mechanism underlying drug resistance to EGFR and HER2 tyrosine kinase inhibitors and to endocrine therapy in the treat...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0528-9

    authors: Ren XR,Wang J,Osada T,Mook RA Jr,Morse MA,Barak LS,Lyerly HK,Chen W

    更新日期:2015-02-15 00:00:00

  • MicroRNAs: shortcuts in dealing with molecular complexity?

    abstract::Recent studies from Clarke's group published in the journal Cell indicate that miRNAs may be the elusive universal stem cell markers that the field of cancer stem cell biology has been seeking. Distinct profiles of miRNAs appear to reflect the state of cell differentiation not only in breast cancer cells, but also in ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2455

    authors: Dontu G,de Rinaldis E

    更新日期:2010-01-01 00:00:00

  • Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?

    abstract::Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these p...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2250

    authors: Schneider BP,Sledge GW Jr

    更新日期:2009-01-01 00:00:00

  • Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells.

    abstract:BACKGROUND:Acquirement of resistance is always associated with a highly aggressive phenotype of tumor cells. Recent studies have revealed that Annexin A2 (Anxa2) is a key protein that links drug resistance and cancer metastasis. A high level of Anxa2 in cancer tissues is correlated to a highly aggressive phenotype. Inc...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-019-1147-7

    authors: Fan Y,Si W,Ji W,Wang Z,Gao Z,Tian R,Song W,Zhang H,Niu R,Zhang F

    更新日期:2019-05-22 00:00:00